Haemonetics Corporation (HAE) Stock Overview
Explore Haemonetics Corporation’s financial performance, market position, analyst ratings, and future outlook.
Haemonetics Corporation (HAE)
Key Financials
Key Financials
Market Cap
4.9B
P/E Ratio
52.49
EPS (TTM)
$5.01
ROE
0.11%
HAE Stock Analysis & Investment Overview (NYSE)
Our AI-powered analysis of Haemonetics Corporation (NYSE: HAE) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Haemonetics Corporation's NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of HAE on the NYSE shows an RSI of 85.35, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $60.72 for the NYSE listing.
Key metrics behind Haemonetics Corporation's NYSE-traded stock include a P/E ratio of 52.49 and a market capitalization of 4.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of HAE on the NYSE.